Clinical Trial Update: A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 [Phase 1]

View source ↗

Summary

A Phase 1 substudy evaluating Ad-RTS-hIL-12 with veledimex in combination with nivolumab for glioblastoma. The ATI001-102 substudy is completed and results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Ad-RTS-hIL-12 (Adenoviral vector encoding human interleukin-12 under Rheostatic Transcriptional System)
• Veledimex (Veledimex; small-molecule activator of the RheoSwitch Therapeutic System)
• nivolumab (nivolumab)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Glioblastoma | Phase 1 | Status: COMPLETED | Results posted: 2025-08-12